Mineralocorticoid Receptor Antagonist (Potassium Canrenoate) Does Not Influence Outcome in the Treatment of COVID-19-Associated Pneumonia and Fibrosis-A Randomized Placebo Controlled Clinical Trial.

Pharmaceuticals (Basel) · 2022 · PMC8874492 · PMID 35215312

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

may be significantno p-value reported

Numerous reports indicate that the use of mineralocorticoid receptor antagonists (MRAs) may be significant in fibrosis prevention [ 14 , 15 , 16 ].

also in 13,097 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.